BGNE

Shares of BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) have earned an average recommendation of “Buy” from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the […]

BeiGene Ltd. (NASDAQ:BGNE) shares, rose in value on Friday, 05/13/22, with the stock price up by 1.06% to the previous day’s close as strong demand from buyers drove the stock to $132.87. Actively observing the price movement in the last trading, the stock closed the session at $131.48, falling wi

Zacks Investment Research downgraded shares of BeiGene (NASDAQ:BGNE – Get Rating) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning, Zacks.com reports. According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and […]

BeiGene (NASDAQ:BGNE – Get Rating) announced its earnings results on Thursday. The company reported ($4.24) earnings per share for the quarter, missing the consensus estimate of ($4.12) by ($0.12), Briefing.com reports. BeiGene had a negative net margin of 120.15% and a negative return on equity of 32.85%. The firm had revenue of $306.60 million during […]